AU2012311542B2 - Screening methods and uses thereof - Google Patents

Screening methods and uses thereof Download PDF

Info

Publication number
AU2012311542B2
AU2012311542B2 AU2012311542A AU2012311542A AU2012311542B2 AU 2012311542 B2 AU2012311542 B2 AU 2012311542B2 AU 2012311542 A AU2012311542 A AU 2012311542A AU 2012311542 A AU2012311542 A AU 2012311542A AU 2012311542 B2 AU2012311542 B2 AU 2012311542B2
Authority
AU
Australia
Prior art keywords
ligand
ligands
target
construct
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012311542A
Other languages
English (en)
Other versions
AU2012311542A1 (en
Inventor
Bjorn Frendeus
Jenny MATTSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Publication of AU2012311542A1 publication Critical patent/AU2012311542A1/en
Application granted granted Critical
Publication of AU2012311542B2 publication Critical patent/AU2012311542B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
AU2012311542A 2011-09-22 2012-09-20 Screening methods and uses thereof Active AU2012311542B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1116364.9 2011-09-22
GBGB1116364.9A GB201116364D0 (en) 2011-09-22 2011-09-22 Screening methods and uses thereof
PCT/EP2012/068576 WO2013041643A1 (en) 2011-09-22 2012-09-20 Screening methods and uses thereof

Publications (2)

Publication Number Publication Date
AU2012311542A1 AU2012311542A1 (en) 2014-03-20
AU2012311542B2 true AU2012311542B2 (en) 2017-09-21

Family

ID=44937671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012311542A Active AU2012311542B2 (en) 2011-09-22 2012-09-20 Screening methods and uses thereof

Country Status (17)

Country Link
US (1) US10191049B2 (cg-RX-API-DMAC10.html)
EP (1) EP2758532B1 (cg-RX-API-DMAC10.html)
JP (2) JP6370220B2 (cg-RX-API-DMAC10.html)
KR (1) KR102024125B1 (cg-RX-API-DMAC10.html)
CN (2) CN103827302A (cg-RX-API-DMAC10.html)
AU (1) AU2012311542B2 (cg-RX-API-DMAC10.html)
CA (1) CA2848932C (cg-RX-API-DMAC10.html)
DK (1) DK2758532T3 (cg-RX-API-DMAC10.html)
ES (1) ES2690783T3 (cg-RX-API-DMAC10.html)
GB (1) GB201116364D0 (cg-RX-API-DMAC10.html)
HU (1) HUE040567T2 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN01795A (cg-RX-API-DMAC10.html)
PL (1) PL2758532T3 (cg-RX-API-DMAC10.html)
PT (1) PT2758532T (cg-RX-API-DMAC10.html)
RU (1) RU2622089C2 (cg-RX-API-DMAC10.html)
SI (1) SI2758532T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013041643A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
US10575515B2 (en) 2010-05-04 2020-03-03 The General Hospital Corporation Methods and compositions for preserving tissues and organs
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
WO2015076355A1 (ja) * 2013-11-22 2015-05-28 株式会社Molcure 標的分子に結合するポリペプチドの決定方法及び決定システム
JP6687601B2 (ja) 2014-08-07 2020-04-22 ザ ジェネラル ホスピタル コーポレイション 全血サンプルの安定化
CN109651506B (zh) * 2017-10-11 2021-12-07 上海交通大学 一种快速获得抗原特异性抗体的方法
EP4537337A1 (en) * 2022-06-13 2025-04-16 BioInvent International AB Methods of isolating anti-ligands

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004023140A1 (en) * 2002-09-04 2004-03-18 Bioinvent International Ab Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2009079793A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
CA2180140A1 (en) 1993-12-27 1995-07-06 Jeffrey I. Weitz Methods and compositions for inhibiting thrombogenesis
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
PT1157041E (pt) 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
AU2002220236A1 (en) 2000-11-09 2002-05-21 Bionova Pharmaceutials, Inc. A method for identifying the proteome of cells using an antibody library microarray
CN100575489C (zh) * 2003-05-14 2009-12-30 多曼蒂斯有限公司 从多肽全能文库恢复可逆可解折叠多肽的方法
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004023140A1 (en) * 2002-09-04 2004-03-18 Bioinvent International Ab Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2009079793A1 (en) * 2007-12-21 2009-07-02 National Research Council Of Canada Non-aggregating human vh domains

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOEL, E. et al., Infection and Immunity, 1998, vol. 66, no. 1, pages 83-88 *
SHINOHARA, N. et al., Journal of Immunological Methods, 2002, vol. 264, pages 187-194 *
SHINOHARA, N. et al., PNAS, 2000, vol. 97, no. 6, pages 2585-2590 *
WILLIAMS, B. R. et al., Immunology Letters, 2002, vol. 81, pages 141-148 *

Also Published As

Publication number Publication date
KR20140080504A (ko) 2014-06-30
GB201116364D0 (en) 2011-11-02
PT2758532T (pt) 2018-11-07
RU2622089C2 (ru) 2017-06-09
WO2013041643A1 (en) 2013-03-28
IN2014DN01795A (cg-RX-API-DMAC10.html) 2015-05-15
JP6370220B2 (ja) 2018-08-08
JP2018154627A (ja) 2018-10-04
HUE040567T2 (hu) 2019-03-28
ES2690783T3 (es) 2018-11-22
US20140227249A1 (en) 2014-08-14
CN107663238A (zh) 2018-02-06
DK2758532T3 (en) 2018-10-22
CN103827302A (zh) 2014-05-28
CA2848932A1 (en) 2013-03-28
AU2012311542A1 (en) 2014-03-20
EP2758532A1 (en) 2014-07-30
JP2015501289A (ja) 2015-01-15
SI2758532T1 (sl) 2018-12-31
PL2758532T3 (pl) 2018-12-31
RU2014115956A (ru) 2015-10-27
KR102024125B1 (ko) 2019-09-23
US10191049B2 (en) 2019-01-29
CA2848932C (en) 2020-12-29
HK1200486A1 (en) 2015-08-07
EP2758532B1 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
CA2848932C (en) Screening methods and uses thereof
IL181927A (en) Methods for antibody library screening and uses thereof for identifying and/or selecting target entities
US10351970B2 (en) Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
CN107430130A (zh) 方法
KR20140027915A (ko) 단일 세포 내 생체 분자의 동시 검출
Cekaite et al. Protein arrays: a versatile toolbox for target identification and monitoring of patient immune responses
US20260018241A1 (en) Methods of isolating anti-ligands
IL181928A (en) Methods for screening a library of molecules
HK40117257A (en) Methods of isolating anti-ligands

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)